| The TIOB - Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers. | — | Baylor Research Institute | <1 mi |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | <1 mi |
| Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema | Phase 2/3 | AbbVie | <1 mi |
| Harvesting Health: Advancing Nutrition and Wellness for Moms and Babies | N/A | Texas A&M University | <1 mi |
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | Phase 3 | AbbVie | <1 mi |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | <1 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Phase 2/3 | CSL Behring | <1 mi |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | <1 mi |
| A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Phase 2 | AstraZeneca | <1 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) | Phase 3 | AstraZeneca | <1 mi |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | N/A | Endogenex, Inc. | <1 mi |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | Phase 3 | Novo Nordisk A/S | <1 mi |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants | Phase 2 | Crystalys Therapeutics | <1 mi |
| A Study of Dotinurad Versus Allopurinol in Participants With Gout | Phase 3 | Crystalys Therapeutics | <1 mi |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | <1 mi |
| A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH | Phase 3 | GlaxoSmithKline | <1 mi |
| A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH | Phase 3 | GlaxoSmithKline | <1 mi |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Phase 3 | Novo Nordisk A/S | <1 mi |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Phase 3 | NRG Oncology | <1 mi |
| Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy | — | Stanford University | <1 mi |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | <1 mi |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | <1 mi |
| Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer | Phase 3 | Genmab | <1 mi |
| Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer | Phase 3 | NRG Oncology | <1 mi |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | <1 mi |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | <1 mi |
| Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | Phase 1 | St. Jude Children's Research Hospital | <1 mi |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Phase 1 | Therapeutic Advances in Childhood Leukemia Consortium | <1 mi |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | <1 mi |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Childhood Cancer Survivor Study | — | St. Jude Children's Research Hospital | <1 mi |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | <1 mi |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Phase 1/2 | Children's Oncology Group | <1 mi |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Fabry Disease Registry & Pregnancy Sub-registry | — | Genzyme, a Sanofi Company | <1 mi |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | Phase 2 | NRG Oncology | <1 mi |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | Phase 2 | Eli Lilly and Company | <1 mi |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | <1 mi |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | Phase 3 | Children's Oncology Group | <1 mi |
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | Phase 3 | Pfizer | <1 mi |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | <1 mi |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | <1 mi |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | <1 mi |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | Phase 2 | Toray Industries, Inc | <1 mi |
| A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | Phase 3 | GlaxoSmithKline | <1 mi |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer | Phase 3 | Astellas Pharma Global Development, Inc. | <1 mi |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | <1 mi |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase 2 | Acrivon Therapeutics | <1 mi |
| Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL | Phase 2 | Etan Orgel | <1 mi |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | Phase 2 | Children's Oncology Group | <1 mi |
| Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | Phase 3 | AstraZeneca | <1 mi |
| Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | Phase 3 | Summit Therapeutics | <1 mi |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Phase 2/3 | Daiichi Sankyo | <1 mi |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer | Phase 1/2 | SURGE Therapeutics | <1 mi |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | <1 mi |
| Neuroblastoma Biology Study | — | New Approaches to Neuroblastoma Therapy Consortium | <1 mi |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | Phase 3 | Sumitomo Pharma Switzerland GmbH | <1 mi |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | <1 mi |
| Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma | Phase 2 | St. Jude Children's Research Hospital | <1 mi |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer | Phase 3 | AstraZeneca | <1 mi |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | Phase 2 | New Approaches to Neuroblastoma Therapy Consortium | <1 mi |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer | N/A | GOG Foundation | <1 mi |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | <1 mi |
| Registry for Stage 2 Type 1 Diabetes | — | Sanofi | <1 mi |
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | Phase 2 | SAb Biotherapeutics, Inc. | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| Study of ALTO-300 in MDD | Phase 2 | Alto Neuroscience | <1 mi |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| ALTO-207 in Adults With Treatment-resistant Depression (TRD) | Phase 2 | Alto Neuroscience | <1 mi |
| A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Phase 3 | Hoffmann-La Roche | <1 mi |
| Product Surveillance Registry | — | Medtronic | <1 mi |
| Assessment of CCM in HF With Higher Ejection Fraction | N/A | Impulse Dynamics | <1 mi |
| ELEVATE-HFpEF Clinical Study | N/A | Medtronic Cardiac Rhythm and Heart Failure | <1 mi |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | <1 mi |
| SELUTION 4 De Novo Small Vessel IDE Trial | N/A | M.A. Med Alliance S.A. | <1 mi |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Phase 3 | X4 Pharmaceuticals | <1 mi |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Phase 3 | Boehringer Ingelheim | <1 mi |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | <1 mi |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | Phase 3 | Boehringer Ingelheim | <1 mi |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | <1 mi |
| Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF) | N/A | Medtronic Cardiac Ablation Solutions | <1 mi |
| A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain | Phase 2 | Eli Lilly and Company | <1 mi |
| Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | — | Agendia | <1 mi |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Phase 1/2 | Pfizer | <1 mi |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | Phase 3 | BioNTech SE | <1 mi |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | Phase 3 | AstraZeneca | <1 mi |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | Phase 3 | AstraZeneca | <1 mi |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | <1 mi |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | Phase 1/2 | Genmab | <1 mi |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients | — | PrECOG, LLC. | <1 mi |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | Pfizer | <1 mi |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | Phase 1 | Bristol-Myers Squibb | <1 mi |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | Phase 1 | Tizona Therapeutics, Inc | <1 mi |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | <1 mi |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) | Phase 2 | Boehringer Ingelheim | <1 mi |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Phase 3 | Ipsen | <1 mi |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Phase 2 | CG Oncology, Inc. | <1 mi |
| Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Phase 2/3 | Mirati Therapeutics Inc. | <1 mi |
| A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease | Phase 2 | GlaxoSmithKline | <1 mi |
| AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight | Phase 3 | Novo Nordisk A/S | <1 mi |
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Phase 3 | AstraZeneca | <1 mi |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Phase 3 | vTv Therapeutics | <1 mi |
| A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | Phase 2 | Zucara Therapeutics Inc. | <1 mi |
| A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus | Phase 2 | Corxel Pharmaceuticals | <1 mi |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | <1 mi |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | <1 mi |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | Teva Branded Pharmaceutical Products R&D LLC | <1 mi |
| ConsideRAte Study - Splenic Stimulation for RA | N/A | Galvani Bioelectronics | <1 mi |
| A Study to Evaluate Solrikitug in Participants With COPD (ZION) | Phase 2 | Uniquity One (UNI) | <1 mi |
| Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | Phase 1 | I-Mab Biopharma US Limited | <1 mi |
| Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy | Phase 3 | yair lotan | <1 mi |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | <1 mi |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | Phase 3 | AstraZeneca | <1 mi |
| VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | Phase 1/2 | University of Texas Southwestern Medical Center | <1 mi |
| Imaging Acetadote Metabolism in Glioblastoma | Early 1 | University of Texas Southwestern Medical Center | <1 mi |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study | Phase 3 | NRG Oncology | <1 mi |
| CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Crescent Biopharma, Inc. | <1 mi |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Adoptive Cell Therapy Long-term Follow-up (LTFU) Study | Phase 1 | USWM CT, LLC | <1 mi |
| Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | Phase 2 | Tiago Biachi de Castria | <1 mi |
| Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | Phase 3 | Immunovant Sciences GmbH | <1 mi |
| A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | Phase 4 | Takeda | <1 mi |
| A Study of ASP1002 in Adults for Treatment of Solid Tumors | Phase 1 | Astellas Pharma Global Development, Inc. | <1 mi |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Phase 2 | Giselle Sholler | <1 mi |
| Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | Phase 1 | Ono Pharmaceutical Co., Ltd. | <1 mi |
| ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome | — | Stanford University | <1 mi |
| Longitudinal Bladder Cancer Study for Tumour Recurrence | — | Pacific Edge Limited | <1 mi |
| Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Imugene Limited | <1 mi |
| A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | Phase 2 | University of Chicago | <1 mi |
| Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | Phase 1 | University of California, San Francisco | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | Phase 1/2 | AbbVie | <1 mi |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | Phase 3 | GlaxoSmithKline | <1 mi |
| Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | Phase 1/2 | Impact Therapeutics, Inc. | <1 mi |
| Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM | Phase 2 | Massachusetts General Hospital | <1 mi |
| PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | PanTher Therapeutics | <1 mi |
| Early-Onset Colorectal Cancer Patients Too Young for Screening | — | Methodist Health System | <1 mi |
| Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | Phase 1/2 | Neonc Technologies, Inc. | <1 mi |
| Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | Phase 1/2 | University of Texas Southwestern Medical Center | <1 mi |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. | Phase 1 | PMV Pharmaceuticals, Inc | <1 mi |
| A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix | N/A | Varian, a Siemens Healthineers Company | <1 mi |
| Ultra-fractionated Radiotherapy for Rectal Cancer | Phase 1 | University of Texas Southwestern Medical Center | <1 mi |
| Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) | Phase 1 | GlaxoSmithKline | <1 mi |
| Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors | Phase 1/2 | Alyssum Therapeutics | <1 mi |
| Bladder Cancer Screening Trial | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 2 | Tyra Biosciences, Inc | <1 mi |
| Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy | Phase 3 | Clarity Pharmaceuticals Ltd | <1 mi |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies | Phase 1/2 | Carrick Therapeutics Limited | <1 mi |
| Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer | Phase 1 | Arjun Mittra | <1 mi |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Phase 1/2 | Artios Pharma Ltd | <1 mi |
| Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) | Phase 3 | Mayo Clinic | <1 mi |
| [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma | Phase 1 | Orhan Kemal Oz | <1 mi |
| Blue Light Cystoscopy With Cysview® Registry | — | Photocure | <1 mi |
| HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors | Phase 1 | HighField Biopharmaceuticals Corporation | <1 mi |
| Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Phase 1/2 | Rigel Pharmaceuticals | <1 mi |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma | N/A | Dana-Farber Cancer Institute | <1 mi |
| Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | <1 mi |
| A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | Phase 2 | Mirati Therapeutics Inc. | <1 mi |
| Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance | Phase 2 | White River Junction Veterans Affairs Medical Center | <1 mi |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Phase 1/2 | enGene, Inc. | <1 mi |
| A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | Phase 1 | Janux Therapeutics | <1 mi |
| Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer | Phase 1/2 | University of Texas Southwestern Medical Center | <1 mi |
| IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) | Phase 2 | Alice Mims | <1 mi |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | <1 mi |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | Phase 1 | HiberCell, Inc. | <1 mi |
| Asciminib Roll-over Study | Phase 4 | Novartis Pharmaceuticals | <1 mi |
| Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Kura Oncology, Inc. | <1 mi |
| A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer | Phase 3 | Astellas Pharma Global Development, Inc. | <1 mi |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | Phase 2/3 | Celgene | <1 mi |
| NEO100 and High-Grade Meningioma | Phase 2 | Neonc Technologies, Inc. | <1 mi |
| Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER) | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | Phase 1 | ADC Therapeutics S.A. | <1 mi |
| A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | Phase 3 | Aura Biosciences | <1 mi |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Phase 2 | Sameek Roychowdhury | <1 mi |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer | Phase 2 | Cybrexa Therapeutics | <1 mi |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Phase 2 | Fore Biotherapeutics | <1 mi |
| Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants | — | University of Texas Southwestern Medical Center | <1 mi |
| A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | Phase 1/2 | 1ST Biotherapeutics, Inc. | <1 mi |
| Maximizing Laser Therapy Success for Port-Wine Birthmarks in Pediatric Patients | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study | Phase 2 | Uma Borate | <1 mi |
| A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) | Phase 3 | AstraZeneca | <1 mi |
| Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Phase 3 | PedAL BCU, LLC | <1 mi |
| Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery | Phase 2/3 | Sir Mortimer B. Davis - Jewish General Hospital | <1 mi |
| A Study of LM-24C5 For Advanced Solid Tumors | Phase 1/2 | LaNova Medicines Limited | <1 mi |
| A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) | Phase 1 | GlaxoSmithKline | <1 mi |
| Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Newly Diagnosed, Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase 2 | Allogene Therapeutics | <1 mi |
| A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | <1 mi |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors | Phase 1 | Gilead Sciences | <1 mi |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | Phase 1 | Institut de Recherches Internationales Servier | <1 mi |
| A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | Phase 1 | C4 Therapeutics, Inc. | <1 mi |
| Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors | Phase 1 | BioNTech SE | <1 mi |
| A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | Phase 3 | Priothera SAS | <1 mi |
| Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | Phase 1/2 | Recursion Pharmaceuticals Inc. | <1 mi |
| Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers | — | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | Phase 1/2 | Debiopharm International SA | <1 mi |
| A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies | Phase 2 | Curis, Inc. | <1 mi |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Jennifer Saultz | <1 mi |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Phase 1/2 | Turning Point Therapeutics, Inc. | <1 mi |
| DALY II USA/ MB-CART2019.1 for DLBCL | Phase 2 | Miltenyi Biomedicine GmbH | <1 mi |
| An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. | Phase 2 | NGM Biopharmaceuticals, Inc | <1 mi |
| A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients | Phase 3 | Children's Oncology Group | <1 mi |
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 | Phase 2 | University of Alabama at Birmingham | <1 mi |
| Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy | Phase 2/3 | Novartis Pharmaceuticals | <1 mi |
| A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) | Phase 1 | Eli Lilly and Company | <1 mi |
| Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors | Phase 1 | NEOK Bio, Inc. | <1 mi |
| IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL | Phase 1/2 | University of Texas Southwestern Medical Center | <1 mi |
| DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma | Phase 1/2 | Diakonos Oncology Corporation | <1 mi |
| A Study of ZL-1310 in Participants With Selected Solid Tumors | Phase 1/2 | Zai Lab (Shanghai) Co., Ltd. | <1 mi |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | <1 mi |
| Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | Phase 1 | University of Chicago | <1 mi |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Phase 3 | Nuvation Bio Inc. | <1 mi |
| Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer. | Phase 2 | John Waters | <1 mi |
| Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | Phase 2 | Taiho Oncology, Inc. | <1 mi |
| Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors | Phase 1 | Hanmi Pharmaceutical Company Limited | <1 mi |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Phase 1/2 Study of UI-102 in Selected Advanced Cancers | Phase 1/2 | United Immunity, co., Ltd. | <1 mi |
| Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma | Phase 2 | SCRI Development Innovations, LLC | <1 mi |
| Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | Phase 1/2 | Sellas Life Sciences Group | <1 mi |
| Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) Multi-Site RCT | N/A | Medical University of South Carolina | <1 mi |
| Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma | N/A | Mayo Clinic | <1 mi |
| An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Periprostatic Neurolysis in Prostate Cancer | Phase 1 | University of Texas Southwestern Medical Center | <1 mi |
| A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors | Phase 1 | Daiichi Sankyo | <1 mi |
| ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | Phase 1 | Acepodia Biotech, Inc. | <1 mi |
| A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC | Phase 1/2 | Pathos AI, Inc. | <1 mi |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Phase 1 | Kura Oncology, Inc. | <1 mi |
| Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | Phase 1/2 | Estrella Biopharma, Inc. | <1 mi |
| A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | Phase 2 | VA Office of Research and Development | <1 mi |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Phase 3 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant | N/A | M.D. Anderson Cancer Center | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Phase 3 | Incyte Corporation | <1 mi |
| Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors | — | SWOG Cancer Research Network | <1 mi |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | Phase 1/2 | Milton S. Hershey Medical Center | <1 mi |
| A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors | Phase 1 | FBD Biologics Limited | <1 mi |
| A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations | — | Blueprint Medicines Corporation | <1 mi |
| Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | Phase 4 | Novartis Pharmaceuticals | <1 mi |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Phase 2/3 | Replimune, Inc. | <1 mi |
| Phase II Randomized Study of Hypofractionated Versus Conventional Radiotherapy | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Measuring Surgical Recovery After Radical Cystectomy | — | M.D. Anderson Cancer Center | <1 mi |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | Phase 1/2 | ImmVira Pharma Co. Ltd | <1 mi |
| Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | Phase 1 | EMD Serono Research & Development Institute, Inc. | <1 mi |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Phase 3 | Pfizer | <1 mi |
| Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | Phase 3 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | <1 mi |
| A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | <1 mi |
| Sequential Therapy in Multiple Myeloma Guided by MRD Assessments | Phase 2 | University of Alabama at Birmingham | <1 mi |
| A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia | Phase 2 | MeiraGTx, LLC | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan | Phase 2 | AbbVie | <1 mi |
| Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | MOMA Therapeutics | <1 mi |
| Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance | Phase 3 | University of Texas Southwestern Medical Center | <1 mi |
| Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 3 | Revolution Medicines, Inc. | <1 mi |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | N/A | University of Colorado, Denver | <1 mi |
| Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2/3 | Exelixis | <1 mi |
| A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy | Phase 2 | Stemline Therapeutics, Inc. | <1 mi |
| Pan Tumor Rollover Study | Phase 2 | Bristol-Myers Squibb | <1 mi |
| Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations | Phase 2 | Boehringer Ingelheim | <1 mi |
| Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | Phase 3 | NRG Oncology | <1 mi |
| A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Phase 3 | Eli Lilly and Company | <1 mi |
| Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | Phase 2 | Dipenkumar Modi | <1 mi |
| Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 | Phase 2 | Healx Limited | <1 mi |
| Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer | — | Convergent Genomics, Inc. | <1 mi |
| Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| AMT-116 in Patients With Advanced Solid Tumors | Phase 1 | Multitude Therapeutics Inc. | <1 mi |
| The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies | Phase 1/2 | AVM Biotechnology Inc | <1 mi |
| PSMA PET Response Guided SabR in High Risk Pca | Phase 1 | University of Texas Southwestern Medical Center | <1 mi |
| A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | Phase 1 | Regeneron Pharmaceuticals | <1 mi |
| Connect for Cancer Prevention Study (Connect) | — | National Cancer Institute (NCI) | <1 mi |
| Predicting BCG Response | — | Cedars-Sinai Medical Center | <1 mi |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | Phase 3 | BeOne Medicines | <1 mi |
| Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma | Phase 2 | Giselle Sholler | <1 mi |
| Customized TULSA-PRO Ablation Registry | — | Profound Medical Inc. | <1 mi |
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | Phase 3 | Arcus Biosciences, Inc. | <1 mi |
| Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | Phase 1 | OHSU Knight Cancer Institute | <1 mi |
| A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Incyte Corporation | <1 mi |
| Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | Phase 2 | Vanderbilt-Ingram Cancer Center | <1 mi |
| A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer | Phase 1 | Novartis Pharmaceuticals | <1 mi |
| Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors | — | Methodist Health System | <1 mi |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | Phase 3 | AbbVie | <1 mi |
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | Phase 3 | Steba Biotech S.A. | <1 mi |
| An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | N/A | University of Texas Southwestern Medical Center | <1 mi |
| A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Phase 1 | Accutar Biotechnology Inc | <1 mi |
| Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | Phase 1/2 | Plus Therapeutics | <1 mi |
| A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer | — | Cedars-Sinai Medical Center | <1 mi |
| A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases | Phase 1 | A2A Pharmaceuticals Inc. | <1 mi |
| A Study of PYX-201 in Advanced Solid Tumors | Phase 1 | Pyxis Oncology, Inc | <1 mi |
| Outcomes of Focal Ablation for Prostate Cancer | — | University of Texas Southwestern Medical Center | <1 mi |
| Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study | — | M.D. Anderson Cancer Center | <1 mi |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) | Phase 1 | AstraZeneca | <1 mi |
| Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma | Phase 1/2 | Lyell Immunopharma, Inc. | <1 mi |
| A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Phase 1/2 | Merus B.V. | <1 mi |
| A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | Phase 1 | AbbVie | <1 mi |
| Study of SGR-3515 In Participants With Advanced Solid Tumors. | Phase 1 | Schrödinger, Inc. | <1 mi |
| A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | Phase 1 | Eli Lilly and Company | <1 mi |
| Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma | Phase 1/2 | Akouos, Inc. | <1 mi |
| A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors | Phase 1 | NEOK Bio, Inc. | <1 mi |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | <1 mi |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | Phase 1/2 | Curis, Inc. | <1 mi |
| A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors | Phase 1 | Peel Therapeutics Inc | <1 mi |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | Phase 1/2 | Milton S. Hershey Medical Center | <1 mi |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | <1 mi |
| PET/MR for Characterization of Renal Masses (RMs) | — | University of Texas Southwestern Medical Center | <1 mi |
| Study of STP938 (Dencatistat) in Advanced Solid Tumours | Phase 1 | Step Pharma, SAS | <1 mi |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | Phase 1/2 | Biohaven Therapeutics Ltd. | <1 mi |
| Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | — | M.D. Anderson Cancer Center | <1 mi |
| Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women | N/A | M.D. Anderson Cancer Center | <1 mi |
| JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Phase 1 | Jazz Pharmaceuticals | <1 mi |
| CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | Phase 1 | Caribou Biosciences, Inc. | <1 mi |
| A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | Phase 3 | Vor Biopharma | <1 mi |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | Genmab | <1 mi |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | <1 mi |
| Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated With Radiation | — | University of Texas Southwestern Medical Center | <1 mi |
| BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Phase 1 | Bio-Path Holdings, Inc. | <1 mi |
| Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Pancreatic Cancer Early Detection Consortium | — | Arbor Research Collaborative for Health | <1 mi |
| A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY) | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | Phase 1 | Aptevo Therapeutics | <1 mi |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Quality of End-of-Life Care for Children With Cancer | — | Children's Oncology Group | <1 mi |
| A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | Phase 1 | K36 Therapeutics, Inc. | <1 mi |
| A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Kyntra Bio | <1 mi |
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 3 | Revolution Medicines, Inc. | <1 mi |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Phase 3 | Immatics US, Inc. | <1 mi |
| A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer | Phase 1 | Aura Biosciences | <1 mi |
| Study of SGR-1505 in Mature B-Cell Neoplasms | Phase 1 | Schrödinger, Inc. | <1 mi |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors | Phase 1 | Abbisko Therapeutics Co, Ltd | <1 mi |
| Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body | — | Bayer | <1 mi |
| Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer | Phase 2 | Dallas VA Medical Center | <1 mi |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of TAK-505 in Adults With Solid Tumors | Phase 1/2 | Takeda | <1 mi |
| A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | Phase 1 | CStone Pharmaceuticals | <1 mi |
| An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1 | — | University of Texas Southwestern Medical Center | <1 mi |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Phase 3 | Children's Oncology Group | <1 mi |
| Study of ORIC-944 in Patients With Metastatic Prostate Cancer | Phase 1 | ORIC Pharmaceuticals | <1 mi |
| Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI) | — | University of Texas Southwestern Medical Center | <1 mi |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2/3 | Daiichi Sankyo | <1 mi |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy. | — | Texas Woman's University | <1 mi |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | Phase 1/2 | Jazz Pharmaceuticals | <1 mi |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | <1 mi |
| Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | — | Alexion Pharmaceuticals, Inc. | <1 mi |
| A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Phase 1 | Kura Oncology, Inc. | <1 mi |
| FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 | Phase 1 | Eli Lilly and Company | <1 mi |
| Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy | — | Bristol-Myers Squibb | <1 mi |
| A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients | Phase 2 | Teligene US | <1 mi |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Phase 3 | RenovoRx | <1 mi |
| A Study of Daratumumab | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | <1 mi |
| Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC) | — | University of Texas Southwestern Medical Center | <1 mi |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | Phase 2 | AbbVie | <1 mi |
| Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine. | N/A | Pacific Edge Limited | <1 mi |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma | Phase 3 | IDEAYA Biosciences | <1 mi |
| A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | Context Therapeutics Inc. | <1 mi |
| Identification of Metabolic Phenotypes Associated With Melanoma Metastasis | — | University of Texas Southwestern Medical Center | <1 mi |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Phase 2/3 | Global Coalition for Adaptive Research | <1 mi |
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer | Phase 3 | J-Pharma Co., Ltd. | <1 mi |
| Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) | Phase 2 | Stingray Therapeutics | <1 mi |
| A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours | Phase 1/2 | Ipsen | <1 mi |
| Cancer Clinical Trials Financial Reimbursement Program | — | University of Texas Southwestern Medical Center | <1 mi |
| Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | Phase 3 | GlaxoSmithKline | <1 mi |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors | Phase 1 | Nested Therapeutics, Inc | <1 mi |
| A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases | Phase 1 | Arcellx, Inc. | <1 mi |
| Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System | — | RefleXion Medical | <1 mi |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | — | UroGen Pharma Ltd. | <1 mi |
| Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies | Phase 1/2 | Georgiamune Inc | <1 mi |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | Phase 2 | Children's Oncology Group | <1 mi |
| Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix) | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma | Phase 1 | Neomorph, Inc | <1 mi |
| A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | Phase 1 | Whitehawk Therapeutics, Inc. | <1 mi |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Phase 3 | Kura Oncology, Inc. | <1 mi |
| Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy | N/A | University of Virginia | <1 mi |
| AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) | Phase 1/2 | AstraZeneca | <1 mi |
| Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma | Phase 3 | University of Texas Southwestern Medical Center | <1 mi |
| American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry | — | University of Louisville | <1 mi |
| A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | <1 mi |
| Digoxin Medulloblastoma Study | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Phase 1 | Pfizer | <1 mi |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | <1 mi |
| Falcon Real World Evidence Registry | — | Exact Sciences Corporation | <1 mi |
| Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | Phase 2/3 | Taiho Oncology, Inc. | <1 mi |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | Phase 3 | Daiichi Sankyo | <1 mi |
| Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia | Phase 3 | Children's Oncology Group | <1 mi |
| Screening for AL Amyloidosis in Smoldering Multiple Myeloma | — | Tufts Medical Center | <1 mi |
| Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Phase 1/2 | Qurient Co., Ltd. | <1 mi |
| A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer | — | Cedars-Sinai Medical Center | <1 mi |
| Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM | Phase 3 | CarThera | <1 mi |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | Phase 2 | Astellas Pharma Global Development, Inc. | <1 mi |
| Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging. | Phase 3 | University of Alberta | <1 mi |
| Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers | N/A | Piomic Medical | <1 mi |
| A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight | Phase 2 | Eli Lilly and Company | <1 mi |
| SPYRAL GEMINI Pilot Study | N/A | Medtronic Vascular | <1 mi |
| A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs | N/A | New Horizon Medical Solutions | <1 mi |
| Kidney Precision Medicine Project | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| TrialNet Pathway to Prevention of T1D | — | University of South Florida | <1 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | <1 mi |
| Non-Invasive Testing to Evaluate Wound Healing in Diabetes | — | University of Texas Southwestern Medical Center | <1 mi |
| Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets | Phase 2 | Biomea Fusion Inc. | <1 mi |
| A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus | Phase 3 | AstraZeneca | <1 mi |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes | Phase 2 | Novo Nordisk A/S | <1 mi |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Phase 2 | Sparrow Pharmaceuticals | <1 mi |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Hoffmann-La Roche | <1 mi |
| Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial | N/A | Sonavex, Inc. | <1 mi |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes | Phase 3 | Hoffmann-La Roche | <1 mi |
| Assessing the Efficacy of Targeted Home Visits in the Management of Chronic Conditions | N/A | University of Texas Southwestern Medical Center | <1 mi |
| A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM | Phase 3 | AstraZeneca | <1 mi |
| A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | Phase 3 | Vertex Pharmaceuticals Incorporated | <1 mi |
| HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes | Phase 2 | Housey Healthcare ULC | <1 mi |
| Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy | Phase 2 | Biomea Fusion Inc. | <1 mi |
| Bionic Pancreas in CFRD | Phase 3 | Jaeb Center for Health Research | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus | Phase 3 | AstraZeneca | <1 mi |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM | Phase 1/2 | Alnylam Pharmaceuticals | <1 mi |
| Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care | N/A | Elizabeth Arnold | <1 mi |
| Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) | N/A | Abbott Medical Devices | <1 mi |
| DBS for Depression | N/A | Baylor College of Medicine | <1 mi |
| Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression | N/A | Nader Pouratian | <1 mi |
| MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression | N/A | VA Office of Research and Development | <1 mi |
| Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services | — | Beth Israel Deaconess Medical Center | <1 mi |
| Combination of Novel Therapies for CKD Comorbid Depression | Phase 2 | Stony Brook University | <1 mi |
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | N/A | LivaNova | <1 mi |
| Preventing Vulnerable Child Syndrome in the NICU With Cognitive Behavioral Therapy (PreVNT Trial) | N/A | University of Texas Southwestern Medical Center | <1 mi |
| A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | Phase 4 | Axsome Therapeutics, Inc. | <1 mi |
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| Accelerated rTMS for Substance Use Disorder and Depression | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O) | N/A | Baylor College of Medicine | <1 mi |
| BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women | N/A | BTL Industries Ltd. | <1 mi |
| Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol | Phase 3 | Axsome Therapeutics, Inc. | <1 mi |
| A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease | Phase 1/2 | AbbVie | <1 mi |
| Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease | Phase 2 | Lighthouse Pharmaceuticals, Inc. | <1 mi |
| A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | Phase 2 | Eli Lilly and Company | <1 mi |
| A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | Phase 2/3 | Washington University School of Medicine | <1 mi |
| Late Onset Alzheimer's Disease | — | Columbia University | <1 mi |
| [18F]PI-2620 Phase 3 Histopathological Study | Phase 3 | Lantheus Biosciences Ltd. | <1 mi |
| A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | Phase 2/3 | Washington University School of Medicine | <1 mi |
| Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) | Phase 2 | Rong Zhang | <1 mi |
| ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease | N/A | InSightec | <1 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes | Phase 2 | Eli Lilly and Company | <1 mi |
| IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Cultural Modification of an Evidence Based Healthy Lifestyle Intervention for People Post Stroke Who Identify as Hispanic/Latino | N/A | Baylor Research Institute | <1 mi |
| Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation | N/A | The University of Texas at Dallas | <1 mi |
| A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | Phase 2/3 | Pfizer | <1 mi |
| AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Phase 3 | Novo Nordisk A/S | <1 mi |
| AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss | Phase 3 | Novo Nordisk A/S | <1 mi |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Phase 3 | Novo Nordisk A/S | <1 mi |
| Get With The Guidelines-Heart Failure Registry | — | American Heart Association | <1 mi |
| The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial | Phase 4 | VA Office of Research and Development | <1 mi |
| STOP AF First Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | <1 mi |
| Home-based Cardiac Rehabilitation in Heart Failure | Phase 3 | University of Texas Southwestern Medical Center | <1 mi |
| Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | Bristol-Myers Squibb | <1 mi |
| Get With the Guidelines Atrial Fibrillation Registry | — | American Heart Association | <1 mi |
| South Asians and Coronary Plaque Registry | — | University of Texas Southwestern Medical Center | <1 mi |
| Prognostic Value of Hyperpolarized 13C MRI for Clinical Myocardial Viability | — | University of Texas Southwestern Medical Center | <1 mi |
| COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | N/A | Edwards Lifesciences | <1 mi |
| Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy | — | University of Texas Southwestern Medical Center | <1 mi |
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Phase 2 | Cytokinetics | <1 mi |
| Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers | — | University of Texas Southwestern Medical Center | <1 mi |
| Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients | Phase 2 | Baylor Research Institute | <1 mi |
| BoxX-NoAF Clinical Trial | N/A | AtriCure, Inc. | <1 mi |
| Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction | Phase 1/2 | Sardocor Corp. | <1 mi |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Phase 3 | Eidos Therapeutics, a BridgeBio company | <1 mi |
| REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women | Phase 3 | Weill Medical College of Cornell University | <1 mi |
| Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants | N/A | Nationwide Children's Hospital | <1 mi |
| IEEM-Heat and Heart Failure | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Identification of Genomic Predictors of Adverse Events After Cardiac Surgery | — | Brigham and Women's Hospital | <1 mi |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | <1 mi |
| Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions | N/A | Teleflex | <1 mi |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Phase 2/3 | Kardigan, Inc. | <1 mi |
| Quality of Pediatric Resuscitation in a Multicenter Collaborative | — | Children's Hospital of Philadelphia | <1 mi |
| An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease | Phase 3 | Alessandro Doria | <1 mi |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| Cardiogenic Shock Working Group Registry | — | Tufts Medical Center | <1 mi |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | Phase 2 | Novo Nordisk A/S | <1 mi |
| Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions | N/A | Concept Medical Inc. | <1 mi |
| Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System | Phase 2 | Stanford University | <1 mi |
| XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP) | N/A | XVIVO Perfusion | <1 mi |
| ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve | N/A | Edwards Lifesciences | <1 mi |
| Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial | Phase 2/3 | VA Office of Research and Development | <1 mi |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | Phase 3 | Massachusetts General Hospital | <1 mi |
| Polypill for Prevention of Cardiomyopathy | Phase 1/2 | University of Texas Southwestern Medical Center | <1 mi |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | Phase 3 | Intellia Therapeutics | <1 mi |
| A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension | Phase 2 | Retension Pharmaceuticals. Inc. | <1 mi |
| The Fourth Left Atrial Appendage Occlusion Study | N/A | Hamilton Health Sciences Corporation | <1 mi |
| The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery | Phase 4 | University of California, San Francisco | <1 mi |
| Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction | Phase 1 | Sardocor Corp. | <1 mi |
| PARTNER 3 Trial - Aortic Valve-in-Valve | N/A | Edwards Lifesciences | <1 mi |
| FORWARD CAD IDE Study | N/A | Shockwave Medical, Inc. | <1 mi |
| A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction | Phase 3 | Bayer | <1 mi |
| OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels | — | Inova Health Care Services | <1 mi |
| Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass | Phase 3 | Octapharma | <1 mi |
| PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III | N/A | Endotronix, Inc. | <1 mi |
| LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 | Phase 3 | Tenax Therapeutics, Inc. | <1 mi |
| MASA Valve Early Feasibility Study | N/A | PECA Labs | <1 mi |
| Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | Phase 3 | Population Health Research Institute | <1 mi |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | <1 mi |
| Tailored Exercise Training Study Among Adults With HFpEF | Phase 2/3 | University of Texas Southwestern Medical Center | <1 mi |
| Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure | N/A | BrioHealth Solutions, Inc. | <1 mi |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | <1 mi |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | <1 mi |
| Hyperinflation Respiratory Therapies in Cardiac Surgery Patients | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | <1 mi |
| A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | Phase 3 | Colorado Prevention Center | <1 mi |
| A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | Phase 2 | BioMarin Pharmaceutical | <1 mi |
| AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions | N/A | Boston Scientific Corporation | <1 mi |
| Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias | — | Heart Rhythm Clinical and Research Solutions, LLC | <1 mi |
| Improving Veteran Referral to Cardiac Rehabilitation | N/A | VA Office of Research and Development | <1 mi |
| Cardiopulmonary Stress Testing (CPET) AlloSure Study | — | Baylor Research Institute | <1 mi |
| Minima Stent System Post- Approval Study (PAS) | — | Renata Medical | <1 mi |
| NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) | N/A | University of Michigan | <1 mi |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | Alnylam Pharmaceuticals | <1 mi |
| PULSED AF Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | <1 mi |
| Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy | — | Tenaya Therapeutics | <1 mi |
| Efficacy of a Telehealth Delivered Group Lifestyle Balance for People Post Stroke (tGLB-CVA) | N/A | Baylor Research Institute | <1 mi |
| Prevail Global Study | N/A | Medtronic Vascular | <1 mi |
| A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events | Phase 2 | Genentech, Inc. | <1 mi |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Phase 4 | Dennis M. McNamara, MD, MS | <1 mi |
| Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | Phase 2/3 | Merck Sharp & Dohme LLC | <1 mi |
| Cardiac Clearance vs G60 Hip Frailty Index | — | Methodist Health System | <1 mi |
| PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR | N/A | Edwards Lifesciences | <1 mi |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | <1 mi |
| REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities | Phase 3 | Weill Medical College of Cornell University | <1 mi |
| A Polypill for Acute Coronary Syndrome | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure | N/A | Abbott Medical Devices | <1 mi |
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | <1 mi |
| Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation | — | University of Alberta | <1 mi |
| Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF | N/A | University of Texas Southwestern Medical Center | <1 mi |
| A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction | Phase 3 | Bayer | <1 mi |
| The ROle of Compression StocKings in Heart Failure Patients | N/A | University of Maryland, Baltimore | <1 mi |
| PK(Pharmacokinetic) Papyrus Covered Coronary Stent System | N/A | Methodist Health System | <1 mi |
| Optimal Ventilation for Cardiac Arrest | N/A | Children's Hospital of Philadelphia | <1 mi |
| LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF | Phase 3 | Tenax Therapeutics, Inc. | <1 mi |
| Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | N/A | Medtronic Cardiovascular | <1 mi |
| HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women | N/A | Weill Medical College of Cornell University | <1 mi |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | <1 mi |
| Escitalopram in Asthma Patients With Frequent Exacerbation | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects | — | Biometry Inc | <1 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma | Phase 3 | AstraZeneca | <1 mi |
| A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | Phase 3 | GlaxoSmithKline | <1 mi |
| Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | Phase 3 | AstraZeneca | <1 mi |
| A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma | Phase 2 | Kymera Therapeutics, Inc. | <1 mi |
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA) | Phase 3 | AstraZeneca | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | Phase 2 | Pfizer | <1 mi |
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) | Phase 3 | Generate Biomedicines | <1 mi |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | — | Duke University | <1 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | Phase 3 | Eli Lilly and Company | <1 mi |
| Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis | N/A | Surf Therapeutics | <1 mi |
| Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry | — | Duke University | <1 mi |
| A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | Phase 3 | Paradigm Biopharmaceuticals Ltd. | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| RA-PRO PRAGMATIC TRIAL | Phase 3 | University of Alabama at Birmingham | <1 mi |
| Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis | Phase 3 | Medipost, Inc. | <1 mi |
| A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) | Phase 1/2 | Nkarta, Inc. | <1 mi |
| AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain | Phase 3 | Novo Nordisk A/S | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease | Phase 2/3 | Pfizer | <1 mi |
| An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema | N/A | Pulmonx Corporation | <1 mi |
| Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) | Phase 3 | GlaxoSmithKline | <1 mi |
| STRIVE Post-Market Registry Study | — | Olympus Corporation of the Americas | <1 mi |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | <1 mi |
| Targeting Social Function in Anxiety and Eating Disorders | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Clinical Trial on Agitation in Alzheimer's Dementia | Phase 2 | IGC Pharma, LLC | <1 mi |
| Teen Recovery Through Inspiration, Support, and Empowerment | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Recovery Through Inspiration, Support, and Empowerment | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | Phase 2 | AbbVie | <1 mi |
| A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | Phase 2 | Seaport Therapeutics | <1 mi |
| Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | <1 mi |
| Deep Brain Stimulation for Refractory Obsessive-Compulsive Disorder | N/A | Nader Pouratian | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications | — | InSightec | <1 mi |
| A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | Phase 2 | Neuron23 Inc. | <1 mi |
| A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease | Phase 4 | Impax Laboratories, LLC | <1 mi |
| SegwayPD: The Effect of Sensory-augmented Postural Training Using Segway on Motor and Cognitive Function in Individuals With Parkinson's Disease | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus | — | University of Pennsylvania | <1 mi |
| Cutaneous Lupus Registry | — | University of Texas Southwestern Medical Center | <1 mi |
| A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | Phase 1/2 | Nkarta, Inc. | <1 mi |
| A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants | Phase 1 | GlaxoSmithKline | <1 mi |
| Lupus Landmark Study: A Prospective Registry and Biorepository | — | Lupus Research Alliance | <1 mi |
| PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis | Phase 4 | Aurinia Pharmaceuticals Inc. | <1 mi |
| A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis | Phase 4 | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| NARCOMS Registry: A Multiple Sclerosis Registry | — | University of Texas Southwestern Medical Center | <1 mi |
| A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | — | TG Therapeutics, Inc. | <1 mi |
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) | Phase 3 | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years | Phase 2 | ModernaTX, Inc. | <1 mi |
| TSC Biosample Repository and Natural History Database | — | National Tuberous Sclerosis Association | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Study of COYA 302 for the Treatment of ALS | Phase 2 | Coya Therapeutics | <1 mi |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | Phase 2 | Puma Biotechnology, Inc. | <1 mi |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | Phase 2 | SCRI Development Innovations, LLC | <1 mi |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | <1 mi |
| [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | Phase 1/2 | Blue Earth Diagnostics | <1 mi |
| Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer | Phase 1/2 | Incyclix Bio | <1 mi |
| A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | Phase 1 | Hefei TG ImmunoPharma Co., Ltd. | <1 mi |
| GammaPod Registry and Quality of Life Nomogram | — | University of Maryland, Baltimore | <1 mi |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Phase 1/2 | Eli Lilly and Company | <1 mi |
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer | Phase 2 | ALX Oncology Inc. | <1 mi |
| Tirzepatide Weight Loss for MRD+ Early Breast Cancer | Phase 2 | Baylor Research Institute | <1 mi |
| Converting HR+ Breast Cancer Into an Individualized Vaccine | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer | Phase 1 | Novartis Pharmaceuticals | <1 mi |
| Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Phase 3 | BriaCell Therapeutics Corporation | <1 mi |
| Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC | Early 1 | Baylor Research Institute | <1 mi |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | SillaJen, Inc. | <1 mi |
| Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | Phase 1/2 | Ellipses Pharma | <1 mi |
| Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) | Phase 1/2 | Artios Pharma Ltd | <1 mi |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | <1 mi |
| A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | <1 mi |
| Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Phase 3 | Relay Therapeutics, Inc. | <1 mi |
| ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions | N/A | ARTIDIS AG | <1 mi |
| Neratinib in Combination With Ruxolitinib in Patients With mTNBC | Early 1 | Baylor Research Institute | <1 mi |
| Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy | N/A | Deborah Farr, MD | <1 mi |
| Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | Phase 1/2 | Aminex Therapeutics, Inc. | <1 mi |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | Phase 1 | OncoNano Medicine, Inc. | <1 mi |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | <1 mi |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | <1 mi |
| Susan G. Komen's ShareForCures | — | Susan G. Komen Breast Cancer Foundation | <1 mi |
| A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Phase 1/2 | Apollo Therapeutics Ltd | <1 mi |
| A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | Phase 1 | Normunity AccelCo, Inc. | <1 mi |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | <1 mi |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | Phase 3 | AstraZeneca | <1 mi |
| A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Phase 1 | Eli Lilly and Company | <1 mi |
| The PREDICT Registry: | — | PreludeDx | <1 mi |
| Study of AVZO-021 in Patients With Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer | Phase 1 | University of Texas Southwestern Medical Center | <1 mi |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | <1 mi |
| Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort | Phase 2 | Sonya Reid | <1 mi |
| A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | Phase 1/2 | Gilead Sciences | <1 mi |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Phase 1 | Relay Therapeutics, Inc. | <1 mi |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | <1 mi |
| A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | Phase 1/2 | Day One Biopharmaceuticals, Inc. | <1 mi |
| A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | Phase 1/2 | Genentech, Inc. | <1 mi |
| Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer | Phase 1 | Boundless Bio, Inc. | <1 mi |
| Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | Phase 2 | Vanderbilt-Ingram Cancer Center | <1 mi |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | <1 mi |
| Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. | Phase 1/2 | Auricula Biosciences Inc. | <1 mi |
| Multiparametric Image Analysis and Correlation With Outcomes in Lung Cancer Screening and Early Stage Lung Cancer | — | University of Texas Southwestern Medical Center | <1 mi |
| Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) | Phase 1 | University of Texas Southwestern Medical Center | <1 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. | Phase 1 | Bristol-Myers Squibb | <1 mi |
| A Study of VET3-TGI in Patients With Solid Tumors | Phase 1 | KaliVir Immunotherapeutics | <1 mi |
| Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Phase 1/2 | Neonc Technologies, Inc. | <1 mi |
| Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders | Phase 2 | Carl Allen | <1 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Phase 3 | Summit Therapeutics | <1 mi |
| A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer | Phase 1/2 | BioNTech SE | <1 mi |
| A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | Phase 1 | Bristol-Myers Squibb | <1 mi |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Phase 3 | Revolution Medicines, Inc. | <1 mi |
| Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | Phase 1/2 | Genprex, Inc. | <1 mi |
| Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | Phase 1 | Revolution Medicines, Inc. | <1 mi |
| A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | Phase 3 | Zai Lab (Shanghai) Co., Ltd. | <1 mi |
| Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Revolution Medicines, Inc. | <1 mi |
| A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | Phase 1/2 | Hummingbird Bioscience | <1 mi |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | Phase 3 | OncoC4, Inc. | <1 mi |
| A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | Phase 1/2 | LigaChem Biosciences, Inc. | <1 mi |
| Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations | Phase 3 | ArriVent BioPharma, Inc. | <1 mi |
| A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | Puma Biotechnology, Inc. | <1 mi |
| Safety and Durability of Sirolimus for Treatment of LAM | — | University of Cincinnati | <1 mi |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | Phase 2 | Lantern Pharma Inc. | <1 mi |
| A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Conjupro Biotherapeutics, Inc. | <1 mi |
| A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Astellas Pharma Global Development, Inc. | <1 mi |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | <1 mi |
| Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors | Phase 1 | Calico Life Sciences LLC | <1 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Summit Therapeutics | <1 mi |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | Phase 2 | Aadi Bioscience, Inc. | <1 mi |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Phase 1/2 | Turning Point Therapeutics, Inc. | <1 mi |
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | Phase 3 | Mirati Therapeutics Inc. | <1 mi |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | <1 mi |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | <1 mi |
| JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | Phase 1/2 | Jacobio Pharmaceuticals Co., Ltd. | <1 mi |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Phase 1 | Clasp Therapeutics, Inc. | <1 mi |
| Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics | — | OncoHost Ltd. | <1 mi |
| Dabrafenib and/or Trametinib Rollover Study | Phase 4 | Novartis Pharmaceuticals | <1 mi |
| A Study of DM005 in Patients With Advanced Solid Tumors | Phase 1 | Doma Biopharmaceutical（Suzhou）Co., Ltd. | <1 mi |
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | <1 mi |
| Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors | Phase 1 | Innate Pharma | <1 mi |
| LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC | Phase 3 | NovoCure GmbH | <1 mi |
| Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | Phase 1/2 | Tasca Therapeutics | <1 mi |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | Phase 3 | Pfizer | <1 mi |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Phase 2 | Jazz Pharmaceuticals | <1 mi |
| A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Phase 3 | Bayer | <1 mi |
| Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of KK2269 in Adult Participants With Solid Tumors | Phase 1 | Kyowa Kirin Co., Ltd. | <1 mi |
| Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | <1 mi |
| JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer | Phase 3 | University of Texas Southwestern Medical Center | <1 mi |
| Study of XB010 in Subjects With Solid Tumors | Phase 1 | Exelixis | <1 mi |
| Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung | Early 1 | University of Texas Southwestern Medical Center | <1 mi |
| A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | Phase 1 | Dren Bio | <1 mi |
| Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | <1 mi |
| Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | Phase 1 | AstraZeneca | <1 mi |
| A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) | Phase 2 | SCRI Development Innovations, LLC | <1 mi |
| A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| SW-682 in Advanced Solid Tumors | Phase 1 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | <1 mi |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Registry for People With Lung Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | Phase 1 | Pfizer | <1 mi |
| A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) | Phase 3 | Amgen | <1 mi |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Phase 1/2 | PMV Pharmaceuticals, Inc | <1 mi |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Phase 1 | Kura Oncology, Inc. | <1 mi |
| Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer | Phase 2 | Integro Theranostics | <1 mi |
| A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | AbbVie | <1 mi |
| Metabolic Biomarkers in Thoracic Cancers | N/A | University of Texas Southwestern Medical Center | <1 mi |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment | — | Ipsen | <1 mi |
| TReatment for ImmUne Mediated PathopHysiology | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | <1 mi |
| Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | — | European Foundation for Study of Chronic Liver Failure | <1 mi |
| A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) | Phase 2 | Deciphera Pharmaceuticals, LLC | <1 mi |
| A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | Phase 3 | Grifols Therapeutics LLC | <1 mi |
| Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation | — | University of Alberta | <1 mi |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Phase 2 | Mirum Pharmaceuticals, Inc. | <1 mi |
| A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment | — | Ipsen | <1 mi |
| A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH | Phase 2 | GlaxoSmithKline | <1 mi |
| Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics | Phase 1 | PharmaIN | <1 mi |
| Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial | Phase 2 | Samer Gawrieh | <1 mi |
| RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Phase 2 | Altimmune, Inc. | <1 mi |
| Functional Assessment in Liver Transplantation | — | University of California, San Francisco | <1 mi |
| Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV) | Phase 4 | Camille N. Kotton, MD | <1 mi |
| Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population | — | Methodist Health System | <1 mi |
| Veteran-Centered Care for Advanced Liver Disease (Vet-CALD) | N/A | VA Office of Research and Development | <1 mi |
| Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk | Phase 2 | Raymond Chung | <1 mi |
| A-LiNK: Improving Outcomes in Autoimmune Liver Disease | — | Children's Hospital Medical Center, Cincinnati | <1 mi |
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | Phase 3 | Bausch Health Americas, Inc. | <1 mi |
| A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center | — | Methodist Health System | <1 mi |
| The Hepatitis C Transplant Collaborative | — | Baylor Research Institute | <1 mi |
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Phase 3 | Gilead Sciences | <1 mi |
| Non-Invasive Quantification of Liver Health in NASH (N-QUAN) | N/A | Perspectum | <1 mi |
| A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Phase 3 | Pierre Fabre Medicament | <1 mi |
| A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Phase 2 | Daiichi Sankyo | <1 mi |
| A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors | Phase 1 | Conjupro Biotherapeutics, Inc. | <1 mi |
| EGCG for Hepatocellular Carcinoma Chemoprevention | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer | — | Helio Genomics | <1 mi |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | N/A | VA Office of Research and Development | <1 mi |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Phase 1/2 | Tvardi Therapeutics, Incorporated | <1 mi |
| GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC | Phase 1/2 | Eureka Therapeutics Inc. | <1 mi |
| A First in Human Study of PLT012 in Participants With Solid Tumor Cancers | Phase 1 | Pilatus Biosciences Inc | <1 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| Ligufalimab and Cadonilimab in Advanced Liver Cancers | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease | Phase 2 | Delcath Systems Inc. | <1 mi |
| A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Phase 1 | Alnylam Pharmaceuticals | <1 mi |
| Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | Phase 1 | Exelixis | <1 mi |
| Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis | Phase 3 | Can-Fite BioPharma | <1 mi |
| A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | Phase 2/3 | AbbVie | <1 mi |
| DESTINY-PANTUMOUR04 | — | AstraZeneca | <1 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | <1 mi |
| Observational Study Protocol: LIVER-R | — | AstraZeneca | <1 mi |
| National Liver Cancer Screening Trial | Phase 4 | University of Texas Southwestern Medical Center | <1 mi |
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years | Phase 4 | Guerbet | <1 mi |
| A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Phase 3 | AstraZeneca | <1 mi |
| Evaluation of Resection Techniques for Pancreatic Tumors | — | Methodist Health System | <1 mi |
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | Phase 2 | Artiva Biotherapeutics, Inc. | 9 mi |
| A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | Phase 3 | UCB Biopharma SRL | 9 mi |
| A Study of PHST001 in Advanced Solid Tumors | Phase 1 | Pheast Therapeutics | 9 mi |
| Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies | Phase 1/2 | PharmaMar | 9 mi |
| A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus | Phase 3 | AstraZeneca | 9 mi |
| A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Phase 4 | Eli Lilly and Company | 9 mi |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Phase 3 | Hoffmann-La Roche | 9 mi |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | 9 mi |
| A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | Phase 1 | IDEAYA Biosciences | 9 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | Phase 3 | AstraZeneca | 9 mi |
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | 9 mi |
| Study of GS-0151 in Participants With Rheumatoid Arthritis | Phase 1 | Gilead Sciences | 9 mi |
| A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | Phase 1 | Biohaven Therapeutics Ltd. | 9 mi |
| Registry Study for Radiation Therapy Outcomes | — | Proton Collaborative Group | 9 mi |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | Phase 1/2 | Pfizer | 9 mi |
| A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | 9 mi |
| Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | 9 mi |
| Study of APR-1051 in Patients With Advanced Solid Tumors | Phase 1 | Aprea Therapeutics | 9 mi |
| A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | Phase 1/2 | Merck Sharp & Dohme LLC | 9 mi |
| A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Phase 1/2 | CStone Pharmaceuticals | 9 mi |
| A Phase 1 Study of IM-1021 in Participants With Advanced Cancer | Phase 1 | Immunome, Inc. | 9 mi |
| A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | Phase 1 | ArriVent BioPharma, Inc. | 9 mi |
| A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors | Phase 1 | Janssen Research & Development, LLC | 9 mi |
| Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Phase 1 | ImmunoGenesis | 9 mi |
| A Study of YL201 in Patients With Advanced Solid Tumors | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | 9 mi |
| Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors | Phase 1 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 9 mi |
| A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation | Phase 1 | Bayer | 9 mi |
| Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors | Phase 1 | Gilead Sciences | 9 mi |
| A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) | Phase 1 | Merck Sharp & Dohme LLC | 9 mi |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors | Phase 1 | Vividion Therapeutics, Inc. | 9 mi |
| Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up | — | Center for Biomedical Research, LLC | 9 mi |
| An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | 9 mi |
| PAS-004 in Patients With Advanced Solid Tumors | Phase 1 | Pasithea Therapeutics Corp. | 9 mi |
| Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors | Phase 1 | Tagworks Pharmaceuticals BV | 9 mi |
| A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | Erasca, Inc. | 9 mi |
| A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Phase 1/2 | Takeda | 9 mi |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Amgen | 9 mi |
| Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors | Phase 1 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 9 mi |
| Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors | Phase 1 | MediLink Therapeutics (Suzhou) Co., Ltd. | 9 mi |
| AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors | Phase 1 | Amgen | 9 mi |
| Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy | — | Massachusetts General Hospital | 9 mi |
| A Study of HS-20110 in Participants With Advanced Solid Tumors | Phase 1 | Hansoh BioMedical R&D Company | 9 mi |
| A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Phase 1 | Innovent Biologics (Suzhou) Co. Ltd. | 9 mi |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | Phase 1 | Vividion Therapeutics, Inc. | 9 mi |
| Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | Phase 2/3 | Pfizer | 9 mi |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | 9 mi |
| STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | Phase 1/2 | STORM Therapeutics LTD | 9 mi |
| Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer | Phase 1 | Amgen | 9 mi |
| Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer | Phase 3 | Pfizer | 9 mi |
| A Study of DS5361b in Participants With Advanced Solid Tumors | Phase 1 | Daiichi Sankyo | 9 mi |
| BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) | Phase 1/2 | Avenzo Therapeutics, Inc. | 9 mi |
| A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors | Phase 1/2 | Crinetics Pharmaceuticals Inc. | 9 mi |
| Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer | Phase 1/2 | Pfizer | 9 mi |
| Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss | Phase 2 | Veru Inc. | 9 mi |
| A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants | Phase 1/2 | DualityBio Inc. | 9 mi |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | Phase 3 | Pfizer | 9 mi |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | Phase 1/2 | Tubulis GmbH | 9 mi |
| A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | Phase 1/2 | Astellas Pharma Global Development, Inc. | 9 mi |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | 9 mi |
| A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | Phase 1 | Incendia Therapeutics | 9 mi |
| A 2-part Phase 1/2 Open-label Trial on ODM-212 | Phase 1/2 | Orion Corporation, Orion Pharma | 9 mi |
| Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan | Phase 1 | AbbVie | 9 mi |
| A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors | Phase 1 | AbbVie | 9 mi |
| A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | Phase 1 | Astellas Pharma Inc | 9 mi |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Phase 3 | Amgen | 9 mi |
| AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors | Phase 1 | Avacta Life Sciences Ltd | 9 mi |
| A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | Phase 1 | Nuvectis Pharma, Inc. | 9 mi |
| Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers | Phase 1/2 | Pfizer | 9 mi |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Phase 1/2 | Revolution Medicines, Inc. | 9 mi |
| A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors | Phase 1/2 | Bayer | 9 mi |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Phase 1/2 | Tango Therapeutics, Inc. | 9 mi |
| A Phase 1 Study of IM-1617 in Participants With Advanced Cancer | Phase 1 | Immunome, Inc. | 9 mi |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | 9 mi |
| Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | Phase 2/3 | Pfizer | 9 mi |
| FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC | Phase 1/2 | Tubulis GmbH | 9 mi |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Phase 1 | BeOne Medicines | 9 mi |
| A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Phase 1/2 | OncoResponse, Inc. | 9 mi |
| Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | 9 mi |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | 9 mi |
| A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | Phase 1/2 | IDEAYA Biosciences | 9 mi |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Phase 3 | Amgen | 11 mi |
| A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | Phase 2 | AbbVie | 12 mi |
| A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus | Phase 3 | Janssen Research & Development, LLC | 12 mi |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | 12 mi |
| A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass | — | Cleo Diagnostics Ltd | 12 mi |
| Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity | Phase 2 | Kailera | 12 mi |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Phase 2 | Eli Lilly and Company | 12 mi |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Phase 3 | Bristol-Myers Squibb | 12 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) | Phase 3 | Bristol-Myers Squibb | 12 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | 12 mi |
| A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | Phase 2 | AstraZeneca | 12 mi |
| A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults | Phase 1 | UCB Biopharma SRL | 12 mi |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | Phase 3 | Takeda | 12 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) | Phase 3 | AstraZeneca | 12 mi |
| Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants | Phase 1 | AstraZeneca | 12 mi |
| A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) | Phase 2 | Boehringer Ingelheim | 12 mi |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | 89bio, Inc. | 12 mi |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Phase 3 | 89bio, Inc. | 12 mi |
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Eccogene | 12 mi |
| Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Phase 3 | Intra-Cellular Therapies, Inc. | 13 mi |
| Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. | Phase 2 | LB Pharmaceuticals Inc. | 13 mi |
| A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression | Phase 2 | Draig Therapeutics Ltd | 13 mi |
| Psychosocial Burden and Quality of Life in Caretakers of Hepatobiliary Cancer Patients | — | Methodist Health System | 13 mi |
| Volume Outcome Relationships and Effects | — | Methodist Health System | 13 mi |
| A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | Phase 3 | Pfizer | 13 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | Phase 2 | AbbVie | 13 mi |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | Phase 2 | AbbVie | 13 mi |
| Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | Phase 3 | Vanda Pharmaceuticals | 13 mi |
| Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation | N/A | The University of Texas at Dallas | 13 mi |
| Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes | Phase 3 | Kailera | 13 mi |
| Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | Phase 3 | Kailera | 13 mi |
| A Study of Brenipatide in Adult Participants With Major Depressive Disorder | Phase 3 | Eli Lilly and Company | 13 mi |
| A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression | Phase 2 | Draig Therapeutics Ltd | 13 mi |
| A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) | Phase 2 | atai Therapeutics, Inc. | 13 mi |
| Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | 13 mi |
| A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | 13 mi |
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 13 mi |
| AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea | Phase 3 | Novo Nordisk A/S | 13 mi |
| AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea | Phase 3 | Novo Nordisk A/S | 13 mi |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Phase 3 | Boehringer Ingelheim | 13 mi |
| A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease | Phase 1 | Verve Therapeutics, Inc. | 13 mi |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight | Phase 3 | Eli Lilly and Company | 13 mi |
| Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | 13 mi |
| Triage Survey for Psychiatry Research Eligibility | — | Adams Clinical | 13 mi |
| Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers. | Phase 4 | Royal Biologics | 13 mi |
| Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease | Phase 3 | Vor Biopharma | 17 mi |
| A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System | N/A | Biosense Webster, Inc. | 18 mi |
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | N/A | Shockwave Medical, Inc. | 18 mi |
| Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure | N/A | Procyrion | 18 mi |
| A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | Phase 4 | GlaxoSmithKline | 18 mi |
| Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | Phase 2/3 | National Cancer Institute (NCI) | 18 mi |
| Asthma Intervention With Residential Ventilation and Air Cleaner (AIRVAC) Study | N/A | The University of Texas at Arlington | 18 mi |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Phase 3 | MoonLake Immunotherapeutics AG | 18 mi |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | Phase 2 | Celgene | 18 mi |
| A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | Phase 3 | Merus B.V. | 18 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Phase 3 | Xenon Pharmaceuticals Inc. | 18 mi |
| A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) | Phase 2 | Tonix Pharmaceuticals, Inc. | 18 mi |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Phase 3 | Cybin IRL Limited | 18 mi |
| Prospective Long-Term Outcomes of a Standardized Ross Procedure | — | Baylor Research Institute | 18 mi |
| Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR | — | Baylor Research Institute | 18 mi |
| MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels | N/A | Concept Medical Inc. | 18 mi |
| The JenaValve ALIGN-AR LVAD Registry | N/A | JenaValve Technology, Inc. | 18 mi |
| ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | N/A | JenaValve Technology, Inc. | 18 mi |
| Medtronic Cardiac Surgery PMCF Registry | — | Medtronic Cardiac Surgery | 18 mi |
| Clinical Study of the inQB8 TTVR System (The MonarQ Study) | N/A | inQB8 Medical Technologies, LLC | 18 mi |
| The CONFORM Pivotal Trial | N/A | Conformal Medical, Inc | 18 mi |
| CALM Study: Cardiomems Assisted Lvad Management | N/A | Baylor Research Institute | 18 mi |
| Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI) | N/A | Supira Medical | 18 mi |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | 18 mi |
| A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy | Phase 2 | Imbria Pharmaceuticals, Inc. | 18 mi |
| Analysis of Coronary Reactivity Testing With and Without Intracoronary Nitrate Testing | N/A | Baylor Research Institute | 18 mi |
| J-Valve Transfemoral Pivotal Study | N/A | JC Medical, Inc., an affiliate of Edwards Lifesciences LLC | 18 mi |
| EFS of the CardioMech MVRS | N/A | CardioMech AS | 18 mi |
| A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation | N/A | Biosense Webster, Inc. | 18 mi |
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | Phase 3 | Icahn School of Medicine at Mount Sinai | 18 mi |
| ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves | N/A | Edwards Lifesciences | 18 mi |
| Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure | N/A | Boston Scientific Corporation | 18 mi |
| Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement | N/A | University of British Columbia | 18 mi |
| Phase 1b/2 Study of IV Sarilumab in Adult With RA | Phase 1/2 | Sanofi | 18 mi |
| MDR - PMCF Study for Taperloc Complete Stems | — | Zimmer Biomet | 18 mi |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease | Phase 1 | Cullinan Therapeutics Inc. | 18 mi |
| RE104 Safety and Efficacy Study in Generalized Anxiety Disorder | Phase 2 | Reunion Neuroscience Inc | 18 mi |
| TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age | — | State University of New York at Buffalo | 18 mi |
| A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder | Phase 2 | VistaGen Therapeutics, Inc. | 18 mi |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus | Phase 1 | Cullinan Therapeutics Inc. | 18 mi |
| Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | Phase 3 | Sanofi | 18 mi |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase 3 | Novartis Pharmaceuticals | 18 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Phase 1/2 | Hoffmann-La Roche | 18 mi |
| Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2/3 | AbbVie | 18 mi |
| Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | 18 mi |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 18 mi |
| A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY) | Phase 2 | Elevara Medicines Limited | 18 mi |
| Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | Phase 3 | Novartis Pharmaceuticals | 18 mi |
| A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) | Phase 1 | AbbVie | 18 mi |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | Phase 3 | Amgen | 18 mi |
| A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States | — | Janssen Research & Development, LLC | 18 mi |
| Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | Phase 2 | Protara Therapeutics | 18 mi |
| A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | Phase 3 | UroGen Pharma Ltd. | 18 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 | Bristol-Myers Squibb | 18 mi |
| Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes | N/A | The University of Texas at Arlington | 18 mi |
| Sacral Neuromodulation for Male Overactive Bladder (MOAB) | N/A | Axonics, Inc. | 18 mi |
| Effects of Exercise and Virtual Reality on Depression | N/A | The University of Texas at Arlington | 18 mi |
| Left vs Left Randomized Clinical Trial | N/A | Baylor College of Medicine | 18 mi |
| Exploring Virtual Reality Adventure Training Exergaming | N/A | The University of Texas at Arlington | 18 mi |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus | Phase 2 | Ventus Therapeutics U.S., Inc. | 18 mi |
| Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | Phase 2 | Zura Bio Inc | 18 mi |
| Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | Phase 2 | AstraZeneca | 19 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease | Phase 2 | AbbVie | 20 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) | Phase 2/3 | Bristol-Myers Squibb | 20 mi |
| A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | Phase 3 | EMD Serono Research & Development Institute, Inc. | 21 mi |
| FX Shoulder Prospective Clinical Study | — | FX Shoulder Solutions | 21 mi |
| A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | Phase 3 | Amgen | 22 mi |
| Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients | Phase 3 | University of Pennsylvania | 22 mi |
| A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus | Phase 3 | AstraZeneca | 22 mi |
| A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU) | Phase 2 | Palvella Therapeutics, Inc. | 23 mi |
| A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis | Phase 2 | Janssen Research & Development, LLC | 24 mi |
| A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | Phase 1 | Climb Bio, Inc. | 24 mi |
| A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease | Phase 3 | EMD Serono Research & Development Institute, Inc. | 24 mi |
| Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | Phase 2 | Pharming Technologies B.V. | 24 mi |
| Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients | Phase 3 | Intra-Cellular Therapies, Inc. | 24 mi |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 24 mi |
| A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer | Phase 1 | Totus Medicines | 24 mi |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Phase 2/3 | Bristol-Myers Squibb | 24 mi |
| A Study of Obexelimab in Patients With Systemic Lupus Erythematosus | Phase 2 | Zenas BioPharma (USA), LLC | 25 mi |
| The Ailliance Post-Market Clinical Study | N/A | Medtronic Spinal and Biologics | 26 mi |
| A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) | Phase 3 | EMD Serono Research & Development Institute, Inc. | 26 mi |
| Breast Mapping and Detection of Suspicious Breast Lesions Using Feminai | — | Feminai | 26 mi |
| A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis | Phase 2 | Vertex Pharmaceuticals Incorporated | 27 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer | Phase 2 | AbbVie | 31 mi |
| A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | Phase 2 | Eli Lilly and Company | 31 mi |
| Study of NTB-928 in R/R OC | Phase 1 | TeneoSeven, Inc. | 31 mi |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | Phase 3 | Merck Sharp & Dohme LLC | 31 mi |
| Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease | Phase 2 | St. Jude Children's Research Hospital | 31 mi |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | Phase 2 | Memorial Sloan Kettering Cancer Center | 31 mi |
| Web-Based Program in Helping Patients With Head and Neck Cancer Adhere to Swallowing Exercises and Coping Strategies | Phase 2 | M.D. Anderson Cancer Center | 31 mi |
| First In Human Study of CX-801 in Advanced Solid Tumors | Phase 1 | CytomX Therapeutics | 31 mi |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | Phase 2 | Verastem, Inc. | 31 mi |
| CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | Phase 2 | TORL Biotherapeutics, LLC | 31 mi |
| First In Human Study of CX-2051 in Advanced Solid Tumors | Phase 1 | CytomX Therapeutics | 31 mi |
| Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis | — | AO Innovation Translation Center | 31 mi |
| Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | Phase 2/3 | Kartos Therapeutics, Inc. | 31 mi |
| International Pediatric Adrenocortical Tumor Registry | — | St. Jude Children's Research Hospital | 31 mi |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | Phase 2 | Verastem, Inc. | 31 mi |
| A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | Phase 3 | Merck Sharp & Dohme LLC | 31 mi |
| A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | Phase 2 | Janssen Research & Development, LLC | 31 mi |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) | Phase 1/2 | Merck Sharp & Dohme LLC | 31 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | Phase 3 | Merck Sharp & Dohme LLC | 31 mi |
| A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | 31 mi |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Phase 2 | AbbVie | 31 mi |
| A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | Phase 3 | Celgene | 31 mi |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) | Phase 3 | Merck Sharp & Dohme LLC | 31 mi |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | Phase 3 | AstraZeneca | 31 mi |
| A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | Phase 3 | Daiichi Sankyo | 31 mi |
| First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect. | Phase 1 | Allterum Therapeutics, Inc | 31 mi |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Phase 3 | Lyell Immunopharma, Inc. | 31 mi |
| Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma | Phase 1 | Cook Children's Health Care System | 31 mi |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Phase 3 | Verastem, Inc. | 31 mi |
| A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 4 | Eli Lilly and Company | 31 mi |
| Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause | N/A | Texas Christian University | 31 mi |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Phase 3 | Cybin IRL Limited | 31 mi |
| Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type | Phase 3 | Suven Life Sciences Limited | 31 mi |
| AngelMed Guardian® System PMA Post Approval Study | — | Angel Medical Systems | 31 mi |
| A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma | — | Children's Oncology Group | 31 mi |
| Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders | Phase 3 | Ascendis Pharma A/S | 31 mi |
| Individualizing Treatment for Asthma in Primary Care (Full Study) | Phase 4 | DARTNet Institute | 31 mi |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | Phase 3 | Takeda | 31 mi |
| Massage Therapy After Thoracic or Lumbar Surgery | N/A | Cook Children's Health Care System | 31 mi |
| Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial | Phase 4 | NephroNet, Inc. | 31 mi |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | Hoffmann-La Roche | 31 mi |
| IKS014 in Advanced Solid Tumors That Express HER2 | Phase 1 | Iksuda Therapeutics Ltd. | 31 mi |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | Phase 1 | Incyte Corporation | 31 mi |
| A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer | Phase 3 | AstraZeneca | 31 mi |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Hoffmann-La Roche | 31 mi |
| ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | 31 mi |
| A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | Phase 1 | Bristol-Myers Squibb | 31 mi |
| Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | 31 mi |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | 31 mi |
| ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer | Phase 2 | iLeukon Therapeutics, Inc. | 31 mi |
| A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) | Phase 3 | Bristol-Myers Squibb | 31 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | AstraZeneca | 31 mi |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Hoffmann-La Roche | 31 mi |
| Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Phase 1 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 31 mi |
| Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes | N/A | Insulet Corporation | 31 mi |
| GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes | N/A | Medtronic MiniMed, Inc. | 31 mi |
| PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes | Phase 4 | Brigham and Women's Hospital | 31 mi |
| Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator | N/A | Zoll Medical Corporation | 31 mi |
| Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | Phase 2 | Regeneron Pharmaceuticals | 31 mi |
| A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) | Phase 2 | Pfizer | 31 mi |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment | Phase 3 | AstraZeneca | 31 mi |
| ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults | Phase 2 | Enveda Therapeutics | 31 mi |
| Depemokimab Asthma Imaging and Bronchoscopy Sub-Study | Phase 3 | GlaxoSmithKline | 31 mi |
| A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Hoffmann-La Roche | 31 mi |
| Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS | N/A | Philip Morris Products S.A. | 31 mi |
| A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) | Phase 2 | Windward Bio | 31 mi |
| Strategic Targeting for Optimal Prevention of Cancer | — | ClinLogic LLC | 32 mi |
| A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | Phase 2/3 | UCB Biopharma SRL | 36 mi |
| A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | Phase 3 | Shanghai Henlius Biotech | 36 mi |
| A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | Phase 2/3 | argenx | 36 mi |
| Phosphatidylethanol and Other Ethanol Consumption Markers | N/A | The University of Texas Health Science Center at San Antonio | 36 mi |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Phase 1 | Hoffmann-La Roche | 36 mi |
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | 36 mi |